Lung Cancer ScreeningNCT06872723
CPRIT: Patient Adherence to Lung Cancer Screening
An observational study of Lung Cancer Screening, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To understand participants' barriers to lung cancer screening and their experience with scheduling lung cancer screening. Read more about this study
- Who is it for?
- Ages 50 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer Screening
- What is being tested?
- Lung Cancer Screening
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 340 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Mar 2025to 28 Feb 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: MD Anderson Cancer Center
Who may be able to join
- Current smoker or quit within the past 15 years
- A 20+ pack-year smoking history
- Healthy enough for treatment
Who cannot join
- Not applicable as our focus is on patients with an order for screening at the UTMB or UT Tyler
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Robert Volk, PHD, 713-563-2509, bvolk@mdanderson.org
About this study
To understand participants' barriers to lung cancer screening and their experience with scheduling lung cancer screening.
Read the detailed description
Primary Objectives/Aims
- Determine rates of lung cancer scheduling and screening at the UTMB and UT Tyler LCS programs.
- Using state-of-the-art machine learning (ML) approaches, develop prediction models for adherence to screening guidelines for newly eligible and established patients. Investigators will leverage data from BRFSS, UT Tyler and UTMB to develop and validate the prediction model, ensuring its generalizability and accuracy.
- Survey participants in the LCS programs about their impressions and experience with the scheduling and completing screening; conduct interviews with participants who receive an order for LCS but do not complete screening by their due date.
- Interview LCS program directors and staff about barriers and facilitators of increasing screening rates in their programs.
- Conditions
- Lung Cancer Screening
- Being tested
- Lung Cancer Screening
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lung Cancer ScreeningBehavioural
Participants who agree to take part in this study, will participate in an interview. During the interview, participants may be asked about: • Participants background information, such as your race and level of education • Participants lung cancer diagnosis and your history of lung cancer screening • Participants experience with scheduling lung cancer screening • Any barriers that kept participants from completing screening
| Study group | Role | What they receive |
|---|---|---|
| Lung Cancer Screening | Participants who agree to take part in this study, will participate in an interview. During the interview, participants may be asked about:
* Participants background information, such as your race and level of education
* Participants lung cancer diagnosis and your history of lung cancer screening
* Participants experience with scheduling lung cancer screening
* Any barriers that kept participants from completing screening Receives: Behavioral: Lung Cancer Screening |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Measured: Through study completion; an average of 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2025
- Study start21 Mar 2025
- Primary completion28 Feb 2029 (estimated)
- Study completion28 Feb 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer ScreeningStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 340 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Robert Volk, PHD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06872723
- Sponsor's protocol ID
- 2024-1489
- Status last verified
- Mar 2025
- First submitted
- 6 Mar 2025
- Last updated
- 2 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CPRIT: Patient Adherence to Lung Cancer Screening
- ClinicalTrials.gov ID
- NCT06872723
- Acronym / sponsor ID
- 2024-1489
- Conditions
- Lung Cancer Screening
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 340 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 21 Mar 2025 (actual)
- Primary completion
- 28 Feb 2029 (estimated)
- Study completion
- 28 Feb 2031 (estimated)
- First posted
- 12 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To understand participants' barriers to lung cancer screening and their experience with scheduling lung cancer screening.
Detailed description
Primary Objectives/Aims
- Determine rates of lung cancer scheduling and screening at the UTMB and UT Tyler LCS programs.
- Using state-of-the-art machine learning (ML) approaches, develop prediction models for adherence to screening guidelines for newly eligible and established patients. Investigators will leverage data from BRFSS, UT Tyler and UTMB to develop and validate the prediction model, ensuring its generalizability and accuracy.
- Survey participants in the LCS programs about their impressions and experience with the scheduling and completing screening; conduct interviews with participants who receive an order for LCS but do not complete screening by their due date.
- Interview LCS program directors and staff about barriers and facilitators of increasing screening rates in their programs.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Lung Cancer Screening | – | Behavioral: Lung Cancer ScreeningParticipants who agree to take part in this study, will participate in an interview. During the interview, participants may be asked about: * Participants background information, such as your race and level of education * Participants lung cancer diagnosis and your history of lung cancer screening * Participants experience with scheduling lung cancer screening * Any barriers that kept participants from completing screening |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- MD Anderson Cancer Center
Key inclusion criteria (3 listed)
- Current smoker or quit within the past 15 years
- A 20+ pack-year smoking history
- Healthy enough for treatment
Key exclusion criteria (1 listed)
- Not applicable as our focus is on patients with an order for screening at the UTMB or UT Tyler
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lung Cancer ScreeningParticipants who agree to take part in this study, will participate in an interview. During the interview, participants may be asked about: • Participants background information, such as your race and level of education • Participants lung cancer diagnosis and your history of lung cancer screening • Participants experience with scheduling lung cancer screening • Any barriers that kept participants from completing screening | Behavioural | Lung Cancer Screening |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2025.
- MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Lung Cancer Screening
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
Active, not recruitingObservational study
Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial
Cancer, Death
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Robert Volk, PHD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer Screening, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Robert Volk, PHD (713-563-2509, bvolk@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2025.